Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
2011

Effects of Rosiglitazone on Vascular Protection

Sample size: 28 publication Evidence: moderate

Author Information

Author(s): Ren Liqun, Liu Naifeng, Zhi Hong, Li Yingjuan, Li Yanzhi, Tang Rining, Sheng Zulong

Primary Institution: Zhongda Hospital of Southeast University, Nanjing, China

Hypothesis

The study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.

Conclusion

Rosiglitazone suppressed VSMC proliferation and early atherosclerotic formation, mediated by reducing local ANG II concentration and modulating angiotensin receptor expression.

Supporting Evidence

  • Rosiglitazone significantly reduced lipid deposition and VSMC proliferation in aortic tissues.
  • VSMC proliferation induced by ANG II was markedly inhibited by rosiglitazone.
  • Rosiglitazone down-regulated AT1R and up-regulated AT2R expression in aortic tissues.

Takeaway

This study found that a drug called rosiglitazone can help protect blood vessels by reducing harmful substances and changing how certain receptors work.

Methodology

Rats were divided into groups and treated with different diets and rosiglitazone, followed by assessments of vascular changes and receptor expression.

Limitations

The study had a small sample size, which may limit the generalizability of the findings.

Participant Demographics

Male Wistar-Kyoto rats, weighing 150-190 g.

Statistical Information

P-Value

p<0.01

Statistical Significance

p<0.01

Digital Object Identifier (DOI)

10.1186/1475-2840-10-10

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication